Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The move up comes as the S&P 500 (SNPINDEX: ^GSPC) ...

Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Deutsche Bank analyst David Hoang initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $176 price target Maximize Your ...

Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...

Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) shares, assigning a Buy rating and setting a price target of $176.00. The new coverage comes with a positive outlook ...

Truist Securities maintained a positive stance on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy rating and a $190.00 ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 6.62M to 5.75M. This put 14.22% of the company's publicly available shares short.